The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells

13Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

The present study investigated the effects of the multikinase inhibitor sorafenib on androgen-independent cancer cells viability and intracellular signaling. Human androgen-independent PC-3 prostate cancer cells were treated with sorafenib. At concentration that suppresses extracellular signal-regulated kinase phosphorylation, sorafenib treatment reduced the mitochondrial transmembrane potential. Sorafenib also down-modulated the levels of myeloid cell leukemia 1, survivin and cellular inhibitor of apoptosis protein 2. Sorafenib induced caspase-3 cleavage and the mitochondrial release of cytochrome c. However, no nuclear translocation of apoptosis inducing factor was detected after treatment and the pan-caspase inhibitor Z-VAD-FMK had an obvious protective effect against the drug. In conclusion, sorafenib induces apoptosis through a caspase-dependent mechanism with down-regulated anti-apoptotic proteins in androgen-independent prostate cancer cells in vitro. © 2010 AJA, SIMM & SJTU All rights reserved.

Cite

CITATION STYLE

APA

Huang, R., Chen, X. Q., Huang, Y., Chen, N., & Zeng, H. (2010). The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian Journal of Andrology, 12(4), 527–534. https://doi.org/10.1038/aja.2010.21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free